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Many  of  the commonly  observed  reproductive  toxicities  associated  with  therapeutic  compounds  can
be  traced  to a disruption  of the  steroidogenic  pathway.  We  sought  to  develop  an  in vitro  assay  that
would  predict  reproductive  toxicity  and  be high  throughput  in  nature.  H295R  cells, previously  validated
as  having  an intact  and  functional  steroidogenic  pathway,  were  treated  with  83  known-positive  and
79  known-negative  proprietary  and  public-domain  compounds.  The  assay  measured  the expression  ofvailable online 13 January 2014
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the  key  enzymes  STAR,  3ˇHSD2,  CYP17A1,  CYP11B2,  CYP19A1,  CYP21A2,  and  CYP11A1  and  the  hormones
DHEA,  progesterone,  testosterone,  and  cortisol.  We  found  that  a Random  Forest  model  yielded  a  receiver
operating  characteristic  area under  the curve  (ROC  AUC)  of 0.845,  with  sensitivity  of  0.724  and  speciﬁcity
of  0.758  for predicting  in vivo  reproductive  toxicity  with this  in  vitro  assay  system.
©  2014  The  Authors.  Published  by Elsevier  Inc.  Open access under CC BY-NC-SA license.. Introduction
Toxicology is in the middle of a profound change, from a descrip-
ive science to a predictive science, mediated by the visionary
oxicity Testing in the 21st Century publication [1]. This approach
as certainly found fertile ground in pharmaceuticals [2]. Some
orm of safety evaluation often occurs very early in the devel-
pment a of compound series. Selection of key compounds for
urther development uses data from multiple assays, each for an
ndividual pathway of toxicity or key biological process [3,4]. The
ody depends on steroid hormones to regulate or inﬂuence the
mmune system, response to stress, gluconeogenesis, components
f behavior, and the many complex parts of male and female
eproduction. Based on the importance of this pathway in many
hysiological processes, it would be beniﬁcial to be able to choose
etween two candidate drug molecules, one of which showed an
nwanted impact on steroidogenesis, and the other of which did
ot. To accommodate the needs of a screening program early in the
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Open access under CC BY-NC-SA candidate selection process, such an assay should require mini-
mal amount of test compound (de novo synthesized drug candidate
molecules), be at least relatively high-throughput, and not require
extended exposures.
In  steroidogenesis, cholesterol is ﬁrst shuttled to the inner mito-
chondrial membrane in a rate-limiting step by steroidogenic acute
regulatory protein (StAR) [5] (Fig. 1). Cholesterol is then converted
to pregnenolone by side chain cleavage enzyme (CYP11A1). Pro-
gesterone is produced by 3 beta-hydroxysteroid dehydrogenase
(3ˇHSD2) action on pregnenolone. CYP17A1 catalyzes the 17-
hydroxylation of pregnenolone and progesterone to 17-hydroxy
intermediates and the 17,20 lyase reactions leading to DHEA and
along with 17beta-hydroxysteroid dehydrogenase (17ˇHSD)  activ-
ity, to testosterone. Cortisol is synthesized from the 17-hydroxy
intermediates by the enzymes 3HSD, 21-hydrolase (CYP21A2),
and 11-beta hydroxylase (CYP11B1). Estradiol is converted from
testosterone by the enzyme aromatase (CYP19A1). Estradiol can
alternatively be converted by17ˇHSD from estrone, a hormone pro-
duced by aromatase activity on androstenedione.
H295R cells are a transformed human adrenal cell line which
secretes all the steroid intermediates of the steroidogenesis path-
way, and has been found useful for studying steroidogenesis [6–9].
These cells are zonally undifferentiated, i.e., they produce the
steroids of each of the three zones normally segregated in the adult
adrenal cortex [10–12]. Because H295R cells uniquely express all
of the enzymes in the steroidogenesis pathway, they allow the
license.
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Fig. 1. The steroidogenesis pathway. Enzymes and transport proteins a
imultaneous testing of all components of steroidogenesis to the
est exposure in vitro. These cells have been widely used in other
esting efforts: the US EPA endocrine disruptor screening program
EDSP), ToxCast, European REACH, as well as the global Organiza-
ion for Economic Cooperation and Development (OECD) [13–15]
ave all employed hormone measurement in the H295R cell model
or identiﬁcation of endocrine disrupting chemicals.
The objective of our work reported here was  to develop
 multi-parameter assay to detect chemical disruption of the
teroidogenesis pathway. The assay would measure quantitative
ifferences in the expression of enzymes in the steroidogenic path-
ay and levels of hormones secreted into the media following
reatment with known in vivo toxicants and non-toxic compounds.
his approach then allowed us to explore whether there was any
elationship between changes in these H295R endpoints and male
r female reproductive system pathology in rats in preclinical safety
tudies. Thus, we  posed the question “how well does one or a com-
ination of steroidogenic endpoints in vitro predict any male or
emale reproductive toxicity in vivo?”
. Materials and methods
.1.  Compound selection
Compounds  that had previously been evaluated in vivo for their
dverse effects on reproductive tissues were selected from Pﬁzer’s
nternal library and from published in vivo studies (Table 1). We
ook an unbiased approach and chose compounds that displayed
eproductive toxicity in either male or females, and incorporated all
eproductive ﬁndings, not just those considered to be hormonally
riven. Not requiring a known mechanism of action for the in vivo
eproductive toxicity was necessary to ensure sufﬁcient power for
he planned model building. It also allowed for us to determine
f an assay focusing on steroidogenic regulation could play a role
n predicting more general reproductive toxicity especially since
ost toxicity testing ends at that level of pathological resolution.
he vast majority of these ﬁndings were of structural abnormalities
i.e., pathology or lesions) noted in reproductive organs after dosing
or periods ranging from 2 weeks to 6 months. We  compiled 83
ompounds with adverse reproductive ﬁndings and 79 compounds
ith no in vivo adverse ﬁnding. Forskolin (Sigma) and prochloraz
Sigma) served as positive controls for the assay. All compounds
ere dissolved in DMSO and DMSO (1%) was used as vehicle control.resented in ovals. Measures hormone endpoints are presented in bold.
2.2.  Cell culture and toxicity assay
H295R (ATCC) cells were cultured at 37 ◦C in 5% CO2
in DMEM:F12 (Invitrogen) medium supplemented with 2.5%
Nu-Serum (BD Biosciences), 1% ITS+ Premix (BD Biosciences), l-
glutamine (Invitrogen), and penicillin-streptomycin (Invitrogen).
Exposures were conducted in 2 phases: dose-range ﬁnding, and
the response phase. For dose-range ﬁnding, cells were plated at
10 × 104 per well in 96 well plates for 48 h before treating with
compounds dissolved in DMSO for 30 h in 8 point curves (2-fold
dilutions, starting at 300 М). Compound effect on cell viability
was determined by using the Cell Titer Glo (Promega) assay kit on
compound-treated cells and results were graphed using the IDBS
XLFit version 4.2.1 plug-in for Microsoft Excel to determine a TC10
(toxic concentration at which 10% cell death is observed) for the
concentration used in the response experiment. If no cytotoxicity
was observed, the cells were treated at 300 M.  The response phase
exposure was  run with cells plated at 10 × 104 cells per well in 96-
well plates for 48 h before compound exposure at the TC10 for an
additional 30 h.
We wanted to determine if the readout from our assay was
correlated with cytotoxicity. We  employed an assay which is com-
monly used in our lab as a general readout of cytotoxicity: the
transformed human liver epithelium cell line [16,17]. THLE-2 cells
(ATCC: CRL2706) were cultured at 37 ◦C in 5% CO2 in BEBM (Lonza)
supplemented with 10% HI-FBS, 5 ng/ml hEGF, 70 ng/ml phospho-
ethanolamine, and the supplied BEBM bullet kit (Lonza). Cells were
plated at 2.5 × 103 cells/well in 384-well plates for 24 h before com-
pound treatment. Compounds were added dissolved in DMSO in
10-point curves with 300 M as the highest concentration. After a
72-h incubation, Cell Titer Glo reagent (Promega) was added. Lumi-
nescence values were read on a luminometer and graphed using the
IDBS XLFit version 4.2.1 plug-in for Microsoft Excel to determine an
IC50 values for cytotoxicity.
2.3.  RNA isolation and quantitative RT-PCR analysis
At time of harvest, the cell supernatants were removed and
frozen, and 100 l lysis buffer was  added to each well in the
96-well plate. The RNA was  then extracted using the SV96 RNA
kit (Promega) according to manufacturer’s instructions. cDNA was
generated using HiCapacity RT kit (ABI #4368813) according to
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Table  1
Model compounds with adverse in vivo reproductive outcomes. In vivo ﬁndings occurred in rat studies unless otherwise noted.
Compound On market name In vivo observed toxicity Compound On market name In vivo observed toxicity
Compound002 Muciﬁcation of vagina, subnuclear
vacuoles in uterus
Compound085 inﬂammation in epididymides
Compound004 Clomiphene Seminal vesicle and prostate gland weights
decreased, reduced testosterone [38]
Compound092 Inﬂammation in epididymides
Compound007 Cefoperazone Testicular degeneration [39] Compound093 Degeneration in testis, abnormal content
in epididymides
Compound009 Vincristine Malformation of late spermatids and arrest
of cell division of spermatocytes and
spermatogonia
Compound094 Dilatation tubules in testis
Compound010 Hypertrophy of interstitial cells in the
testis
Compound096 Estrous cycle disruption, mammary
hyperplasia, decreased seminal vesicles
Compound012 Testicular degeneration Compound098 Inﬂammation in Epididymides
Compound013 Testicular degeneration, decreased ovary
weight
Compound099 Low testosterone
Compound017  Colchicine Degraded microtubules in the testis,
caused abnormalities of the head and
acrosome of testicular spermatids [40]
Compound100  Inﬂammation in Epididymides
Compound018 Inhibits sexual differentiation in gonads Compound101 Testicular degeneration (dog), cervial
polyps
Compound019 Testicular atrpophy, disturbance in rat
estrus cylce
Compound102 Degenerative spermatid cell debris,
Atrophy, delayed estrus cycle
Compound022 Degeneration of seminiferous tubules,
germinal cell degeneration/depletion,
hypospermia, interstitial cell hyperplasia
in the testis, Decrease ovary weights
Compound104 Testicular lesions: germ cell degeneration
and necrosis
Compound024  Testicular degeneration/atrophy Compound105 Testicular lesions: germ cell degeneration
and necrosis
Compound026  Vaginal mucosal atrophy, Vaginal
parakeratosis due to senescence
Compound110 Decreased epididymides and testes
weights
Compound027 Abnormal luminal content, increased giant
cells in seminiferous, necrosis of corpora
lutea in ovaries
Compound111 Testis/epididymis, seminiferous tubules,
spermatocytic degeneration, necrosis,
mammary increases
Compound028  Acyclovir Testicular atrophy, spermatogenesis
(mouse) [41]
Compound112 Decreased prostate/seminal vesicle wt,
delayed sperm release, delayed estrus cycle
Compound029 Nifedipine Reduced weight of the testis and
epididymis, reduced sperm count [42]
Compound116  Grossly small testes and epididymides
spermatogenic arrest in seminiferous
tubules, spermatogenic epithelium was
attenuated
Compound031 Spironolactone Low testosterone levels [43] Compound118 Testis/epididymis, seminiferous tubules,
spermatocytic degeneration, necrosis
Compound032 Low testosterone, leydig and sertoli cells
were decreased
Compound119 Testicular seminiferous tubular
degeneration, epididymal sperm
granulomas, oligospermia and increased
intralumenal cell debris in epididymides
Compound037 Chlorambucil Damage spermatogenesis and cause
testicular damage [44]
Compound122 Seminiferous tubule and epididymal
lesions
Compound039 Flutamide Increases in plasma testosterone level and
Leydig cell hyperplasia, seminiferous
tubular atrophy and degeneration [45]
Compound126  Arteriopathy in Epididymides (dog)
Compound042 Chlorpromazine Decrease in testicular weight [46] Compound128 Testicular giant cells, epdidymal spermatic
granuloma
Compound048 Divalproex Reduced spermatogenesis and testicular
atrophy [47]
Compound129 Germ cell degeneration and necrosis
degeneration of seminiferous
tubulesluminal cellular debris in
epididymes
Compound053 Busulfan Testes, tubules and germinal epithelia
were decreased signiﬁcantly, disrupt
spermatogenesis through affecting both
germ and somatic cells [48]
Compound130 Abnormal testis and Epididymides
Compound057 Theobromine Testicular atrophy with extensive
spermatogenic cell degeneration and
necrosis [49]
Compound135 Seminiferous tubular degenerat,decreased
numbers  of spermatids, sloughing of
degenerate and necrotic cells in the
tubular lumen, presence of giant cells and
vacuolation of Sertoli cells
Compound059 Vacuolation in testis Compound137 Seminiferous tubule degeneration
Compound060 Spermatic Retention in testis, Abnormal
content in Epididymides
Compound138 Testicular degeneration
Compound061 Testicular degeneration Compound139 Testicular degeneration and muscle
necrosis
Compound063 Multifocal dilation of the seminiferous
tubules, stops rat cycles
Compound140 Testicular degeneration, Seminiferous
tubule degeneration
Compound064  Decreased uterine weights, subnuclear
vacuolation, Increased estrous cycle length,
increased number of animals in metestrous
decreased conception, corpora lutea
Compound142 Delayed sperm release
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Table 1 (Continued)
Compound On market name In vivo observed toxicity Compound On market name In vivo observed toxicity
Compound066 Increase in accumulation of cellular debris
in the lumen of the epididymal ducts
Compound143 Lesions in epididymis, bilateral sperm
granuloma
Compound067 Bromocriptine Decrease in testicular testosterone content
and a reduction in plasma testosterone
levels [50]
Compound145 Seminiferous tubule degeneration
Compound068 Testicular degeneration (mouse) Compound147 Seminiferous tubule degeneration
Compound069 Sulfasalazine Abnormal motion of epididymal sperm,
decrease in sperm count and motility [51]
Compound148  Delayed sperm release
Compound070 Acrylamide Destruction of seminiferous tubules,
decrease in the total sperm count [52]
Compound149 Reserpine Atrophy of the interstitial cells of the testis
[53]
Compound071 Testicular atrophy (dog) Compound150 Melphalan Induces testicular damage and affects
sperm variables [54]
Compound074 Low plasma testosterone levels Compound153 Reduced the sperm count and
motility,testicular damage and affected
sperm variables
Compound075  Decreased seminal vesicles(rat), Estrous
cycle disruption, mammary hyperplasia,
Hypertrophy in mammary, decreased
seminal vesicles
Compound155 Ganciclovir Testicular damage and decreased sperm
count [55]
Compound076  Prolonged CL’s in ovaries, mammary
hyperplasia in females, and vaginal
muciﬁcation.
Compound159 Testicular atrophy (dog)
Compound077 Degeneration of pachytene spermatocytes
in the testes
Compound160 Testis weight drop and germ cell apoptosis
Compound080 Low plasma testosterone levels, decrease
epididymides
Compound161 Tubular degeneration in testis, Abnormal
content in Epididymides
Compound082  Luminal ﬂuid decreased in seminal
vesicles, decreased seminal vesicles
Compound162 Increased ovarian follicular cysts,
occasional absence of corpora lutea,
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anufacturer’s instructions. Q-PCR was performed in 384-well
lates using Gene Expression Master Mix  (ABI#4370074) and
BI Inventoried Gene Expression assays: GAPDH (Hs99999905
1) STAR (Hs00264912 m1), 3ˇHSD2 (Hs00605123 m1),
YP17A1 (Hs00164375 m1), CYP11B2 (Hs01597732 m1),
YP19A1 (Hs00903413 m1), CYP21A2 (Hs00416901 g1), CYP11A1
Hs00167984 m1). Values normalized to GAPDH are presented as
old over DMSO.
.4.  Hormone measurement
Hormones  were measured using Multi-Spot 96 HB 4-Spot
ustom Steroid Hormone Panel (Mesoscale Discovery) with
lterations. Brieﬂy, a custom cortisol assay was developed in con-
unction with MesoScale Discovery and cortisol was added to the
vailable 4-plex along with currently provided analytes proges-
erone, DHEA, and testosterone. 50 l of spent culture medium was
un per well in duplicate and values were calculated based on a
tandard curve. Values are represented as percent of DMSO control.
.5. Statistical analysis
The  Supplemental Data (Supplemental Table 1) contain the raw
ata values and computer code in the R programming language
18,19] that can be used to completely reproduce all the calcula-
ions shown in this manuscript.
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.reprotox.
013.12.009.
The assay data were pre-processed prior to modeling. First, there
ere 23 compounds missing at least one data point. These data
ere imputed using the ﬁve nearest-neighbor imputation [20].
lso, some of the analyte distributions were right-skewed and sta-
istical transformations were applied to the data to produce a more
ymmetric distribution. Finally, the analytes were standardized so
hat they have a mean of zero and a standard deviation of one.imbalance in estrous cycle
A variety of statistical models were explored to ﬁnd the best
option for predicting the probability of toxicity. A detailed descrip-
tion of each of these models is given in Hastie et al. [21] and Kuhn
and Johnson [22]. Many of these models have “tuning parame-
ters” which cannot be estimated directly from the data. For these,
the cross-validation procedure was  executed for each value of the
tuning parameter(s) and the best model was  selected based on the
area under the ROC curve. The models, and their tuning parameters,
used here were:
• Random  Forests (RF) is a tree-based ensemble model [23]. Five
values  of the tuning parameter, the number of random selected
analytes  at each split, were used to optimize the model.
• Support Vector Machines (SVM) [24] is a kernel-based machine
learning  method (the radial basis kernel was  used in these mod-
els).  For this model, ﬁve values of the cost parameter were tuned.
Additionally, the method of Caputo et al. [25] was used to analyt-
ically  estimate the radial basis function parameter.
• Nearest Shrunken Centroids (NSC) is a linear classiﬁcation model
with  built-in feature selection. Forty values of the tuning param-
eter,  the shrinkage threshold, were evaluated.
• Naive  Bayes (NB) uses the distribution of each analyte indepen-
dently  to estimate the probability of toxicity [21]. Two different
methods  for estimating the distributions (parametrically and
non-parametrically) were tested.
• Logistic  Regression is a well-known statistical technique that
produces  linear decision boundaries [26]. It will be demonstrated
that  there are many signiﬁcant between-analyte correlations,
which can cause instability in the model and may negatively
affect performance. Because of this, a second order (L2) penalty
will  be used during model ﬁtting to compensate for the collinea-
rity  of the analytes similar to classical ridge regression [27].These models used all of the analytes data produced in the
model (degree of change in gene expression for the steroid synthe-
sis genes, as well as medium levels of steroids). Recursive feature
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limination (RFE) was also used in conjunction of several of these
odels (except NCS). This backwards selection routine ranks the
nalytes by their importance to the model [24]. After the model
ith all analytes was created, the least important analytes were
emoved one at a time, the model was re-ﬁt and performance was
racked. Using this proﬁle of performance, the optimal number of
redictors was determined and the ﬁnal model was  ﬁt using only
he top analytes.
Three  measures of performance were used to characterize the
ffectiveness of the models:
Sensitivity: given that a compound induces reproductive toxicity,
what  is the probability that the compound is predicted as toxic
(a.k.a.  true positive rate).
Speciﬁcity:  given that a compound does not induce reproductive
toxicity, what is the probability that the compound is predicted
as  non-toxic (true negative rate).
Area  under the ROC curve: using the estimated probability of
reproductive  toxicity, the ROC curve tracks the sensitivity and
speciﬁcity  over a continuum of probability cut-offs [28]. The area
under  the curve can be used as a measure that combines sensi-
tivity  and speciﬁcity.
To obtain useful estimates of model performance, cross-
alidation was used on the training set samples [29] given the
ize of the data set. This is a form of “resampling” where ran-
om subsets of the samples are methodically held-back from the
ata set. The model was ﬁt to the majority of the data and the
eld-out samples were predicted. This was repeated multiple times
nd performance was estimated for each of the held-out samples
nd these values were aggregated into a single estimate of perfor-
ance. In these analyses, ﬁve repeats of ten-fold cross-validation
ere used because of its attractive bias and variance properties. In
he end, 50 different hold-out samples of roughly 10% were used to
stimate performance. For recursive feature elimination, the same
ross-validation scheme was utilized to estimate the uncertainty
f the feature selection [30] while an internal cross-validation was
sed to tune the models.
.  Results
.1. Assay performance using prototypical inducers
Development of the steroidogenesis assay in H295R cells
ncluded systematically evaluating different cell plating densities
nd times of sampling (Supplementary material related to this
rticle can be found, in the online version, at http://dx.doi.org/
0.1016/j.reprotox.2013.12.009).  Because the goal of this work was
o  develop a cell-based screen that could be utilized for the evalua-
ion of large compound sets, it would not be possible to use multiple
imepoints in the ﬁnal version of the assay. Conditions were opti-
ized so that the two model compounds, forskolin and prochloraz,
roduced the greatest effect in the assay endpoints. These two  com-
ounds were then used as the assay’s positive controls and included
n each subsequent run. Optimal conditions were determined to be
00,000 cells plated per well plated 48 h before compound addition
nd exposure for an additional 30 h.
Forskolin is an adenylate cyclase activator that raises intracel-
ular cAMP levels. It has been demonstrated to effect the enzymes
f the steroidogenesis pathway as well as increase secreted pro-
esterone and cortisol levels [31]. Treatment of cells with 10 M
orskolin for 30 h resulted in signiﬁcant changes in gene expres-
ion. Robust induction of CYP11B2 (270-fold, p-value <0.0001) was
bserved. Forskolin exposure also produced strong inductions of
YP19A1 (26-fold, p-value <0.0001), CYP21A2 (12.3-fold, p-valueoxicology 45 (2014) 77–86 81
<0.0005),  and HSD32 (24.4-fold, p-value <0.0005), as well as more
mild, but still signiﬁcant increases in CYP11A1 (3.3-fold, p-value
<0.00001), CYP17A1 (6.1-fold, p-value <0.0001), and STAR (5.1-fold,
p-value <0.00001) expression (Fig. 2A). These ﬁndings are similar
in rank order to those reported by others [6]. Based on such gene
changes, one would expect to see increased product being secreted,
and this was the case: the expected increases in the secreted levels
of cortisol (290%, p-value <0.0001) and progesterone (392%, p-value
<0.0005) into the culture medium were observed (Fig. 2B). Minimal
effects on testosterone and DHEA were observed at this time point.
Prochloraz is an antifungal compound that produces instances of
male reproductive toxicity when administered to rats during sexual
differentiation [32,33]. It has been reported to increase proges-
terone levels whilst decreasing testosterone levels in vivo [34].
Exposure of the cells to 4 M prochloraz resulted in a robust
induction of CYP11A2 (97-fold, p-value <0.0001) and modest induc-
tions of CYP19A1 (3.4-fold, p-value <0.0001), CYP21A1 (3.4-fold,
p-value <0.0005), and HSD32 (5.2-fold, p-value <0.001) (Fig. 2C).
Treatment of H295R cells with prochloraz resulted in consider-
able increases in progesterone secretion (1838%, p-value <0.001)
while substantially decreasing the secretion of cortisol (3%, p-value
<10−18), DHEA (7%, p-value <10−18), and testosterone (9%, p-value
<10−17) after 30 h.
3.2.  Compound test set administration
H295R cells were plated at 100,000 cells per well in 96 well
plates for 48 h before compound administration in 8-point curves
with a 300 M starting maximal concentration. Cell Titer Glo
(Promega) assay kit, which measures ATP, was  used as a mea-
sure of cytotoxicity. TC10 (10% unspeciﬁed cytotoxicity) values
were calculated from the curves and used as the treatment dose
in the subsequent effect assay. A single concentration point was
employed in order to enable this assay to be high throughput. The
TC10 concentration was chosen as many known endocrine disrupt-
ors were shown to produce signiﬁcant effects in the assay system
at the TC10 concentration (Ulleras et al.) If no cytotoxicity was
observed, the cells were treated with the compounds at 300 M.
Cells were treated in duplicate wells. The experiment was run under
the previously described optimized conditions. Compound effects
on gene expression of the enzymes in the steroidogenesis pathway
as well as the level of secreted progesterone, testosterone, DHEA,
and cortisol were measured and the results (see supplemental data
Table 1) were used to build the statistical model.
3.3. Predictive modeling
ROC  curve analysis was conducted for each analyte separately
to obtain an initial indication of its utility as a predictor. For each
predictor, a series of thresholds are examined to see if the toxic
and non-toxic compounds can be classiﬁed using a simple cut-off
point. The sensitivities and speciﬁcities resulting from the various
cut-offs are then used to form the predictor’s ROC curve. The area
under that curve is then used to quantify the predictive ability of
each assay. If the assay can differentiate between toxic and non-
toxic compounds on its own, the area under the ROC  curve should
be close to one. The closer to 1, the greater the value that endpoint
has in predicting reproductive toxicity. The areas under the ROC
curves for each individual analyte were: CYP11B1 (0.77), CYP11A1
(0.77), CYP21A1 (0.74), CYP19A1 (0.7), STAR (0.67), CYP11B2 (0.65),
HSD3B2 (0.62), CYP17A1 (0.61), progesterone (0.55), testosterone
(0.54), cortisol (0.54), DHEA (0.46). Here, the RT-PCR assays of gene
expression showed higher individual predictivity of toxicity than
the hormonal assays. However, many of the predictive models that
were used here are able to model complex relationships between
the outcomes and multiple predictors and, because of this, the
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tig. 2. Expression analysis of the enzymes in the steroidogenesis pathway. H295R c
ormalized to GAPDH and presented as fold over DMSO. Hormone secretion into the
nd  is represented as percent of DMSO control. *p-value <0.001, **p-value <0.0001.
ndividual ROC curve results are poorly indicative of the relative
mportance of an individual assay to a ﬁnal comprehensive model.
The cross-validation results are shown in Table 2. The mean and
orresponding standard error were computed for the 50 estimates
f performance produced during the cross-validation process. For
xample, the Naive Bayes model had area under the ROC curve val-
es that were on average 0.756 but, given that the standard error
f the mean was 0.0178, a 95% conﬁdence interval for the mean of
he cross-validation results was (0.720, 0.792). Many of the predic-
ive models showed performance characteristics that were roughly
quivalent, given the samples size. Unlike the other models, the
earest Shrunken Centroid model achieved a reasonable area under
he ROC curve (0.77), but did so by sacriﬁcing model speciﬁcity
0.52) for sensitivity (0.79).
The  performance proﬁles for the models when used in con-
unction with recursive feature elimination are shown in Fig. 3.
lthough Random Forest shows a small decrease in performance as
redictors are removed, the model with the largest area under the
OC curve (random forest) uses all the endpoints as useful predic-
ors. The Naive Bayes model showed an increase in performance up
o 3 analytes (CYP11B1, CYP11A1, and CYP21A1). Logistic Regression
ad small gains when eliminating predictors.
Of these models, we focused on the basic Random Forest model,
hich appeared to perform the best and Naive Bayes with feature
election classiﬁer. Naive Bayes (RFE) was chosen as the compara-
or because it performs the best with fewer endpoints. This model
ould allow the assay to maintain predictive power while elim-
nating the need for hormone measurements and reducing the
ranscriptional endpoints, further enabling the high throughputere treated for 30 h with 10 M forskolin (A) or 4 M prochloraz (C). All values are
a from cells treated with 10 M forskolin (B) or 4 M prochloraz (2D) was  analyzed
ability  of the assay. Random Forest can compute a built-in variable
importance metric that quantiﬁes the loss in performance if each
predictor was  coerced to be non-informative by randomly scram-
bling the data. For example, suppose the testosterone values were
randomly scrambled and new model predictions were calculated.
If performance did not drop by altering this predictor, it would not
be considered important to the model. This same process would
then be applied independently to each predictor. Using this pro-
cess, the list of predictors from most important to least important
is CYP11B1, CYP11A1, CYP21A1, CYP19A1, STAR, CYP11B2, HSD3B2,
CYP17A1, progesterone, testosterone, cortisol, and DHEA. For the
two other models, the number of times that each predictor was
selected for each of the 1 cross-validation iterations can be used to
measure the importance to the models. For Naive Bayes, the same
assays were selected in each cross-validation iteration: CYP11B1,
CYP11A1 and CYP21A1.
Fig.  4 shows the distributions of the class probabilities for the
Random Forest and Naive Bayes models. The histograms show
the probability of reproductive toxicity for each compound that
was held-out during the cross-validation process. The bottom pair
of histograms shows the probability of reproductive toxicity for
compounds that were truly non-toxic in vivo. The Random Forest
model shows the largest proportion of points between 20% and
40% probability. As the predicted probability of reproductive tox-
icity increases, fewer non-toxic compounds are misclassiﬁed as
toxic. For the Bayesian model, a large number of non-toxic com-
pounds have low probabilities (<20% probability) of being called
toxic but, compared to Random Forest; more compounds are con-
ﬁdently mis-predicted as toxic in the Bayesian model. The upper
J.M. Maglich et al. / Reproductive Toxicology 45 (2014) 77–86 83
Table  2
Mean  performance values estimated using cross-validation.
Model Predictors ROC Sensitivity Speciﬁcity
Mean Std. err. Mean Std. err. Mean Std. err.
Logistic Reg 12 0.778 0.014 0.708 0.023 0.704 0.025
Logistic Reg (RFE) 7 0.801 0.014 0.745 0.021 0.731 0.025
Naïve Bayes 12 0.756 0.018 0.657 0.023 0.754 0.023
Naïve Bayes (RFE) 3  0.812 0.015 0.655 0.019 0.780 0.022
NSC 4 0.773 0.017 0.789 0.025 0.524 0.026
Random Forest 12 0.847 0.013 0.724 0.019 0.758 0.023
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oRandom Forest (RFE) 11 0.845 0.0
SVM 12 0.852 0.0
SVM (RFE) 10 0.837 0.0
anels show similar results for the truly reproductive toxicants.
andom Forest shows a broader probability distribution for repro-
uctive toxicants while Naive Bayes tends to conﬁdently predict
eproductive toxicity (correctly or incorrectly).
Since the Random Forest model has a wider distribution of class
robability values, one potential method for improving its perfor-
ance is to institute an equivocal or indeterminate zone for random
orest predictions. Here, we deﬁne a range of probability values
hat are too uncertain to conﬁdently predict the compounds. For
xample, if the predicted probability of reproductive toxicity was
etween 40% and 60%, our conﬁdence in the correctness of that
rediction is low and the compound would not be classiﬁed as
eproductive toxicant or non-toxic. For the Random Forest model,
n equivocal zone between 40% and 60% would exclude, on aver-
ge, 28.9% of the compounds but would increase the area under
he ROC curve from 0.838 to 0.888. This approach would not be
s effective for the Naive Bayes model since fewer compounds are
redicted inside of the potential equivocal zone (as indicated by
he zone between the dotted lines in Fig. 3).The value of this approach increases with the criticality of the
rediction. If one or more independent techniques will be used
o verify the model prediction for a given compound, the equiv-
cal zone may  increase the cost and time of a model prediction.
Fig. 3. Performance proﬁles for different models wh0.751 0.018 0.745 0.025
0.748 0.024 0.791 0.019
0.753 0.020 0.771 0.020
However, if very little evidence exists related to the toxicity of the
compound (as is the case with new pharma candidates), the equiv-
ocal zone can play a pivotal role in increasing our conﬁdence in the
information used to judge a compound.
3.4. Reproductive toxicity predictions are independent of
cytotoxicity
General  cytotoxicity assays have been utilized by the phar-
maceutical industry as a tool to predict in vivo toxicities. One
commonly used assay employs THLE transformed liver cells and
measures the amount of viable cells present by quantiﬁcation of
ATP after treatment with compounds [17]. We  wished to deter-
mine if the predictions from this assay and algorithm was being
driven more by drug effects on cellular health and cytotoxicity than
drug-induced effects on steroidogenesis. THLE cells were treated
with the compound test set in 10-point curves starting at 300 M.
Values were normalized to DMSO and IC50 were determined. The
H295R random forest predictions were compared to the cytotoxic-
ity IC50s in THLE cells (Fig. 5). No correlation was observed between
the cytotoxicity measurement and the prediction of reproductive
toxicity by random forest modeling. This comparison provides con-
ﬁdence that the H295R assay is predicting speciﬁc toxicity due to
en conducting recursive feature elimination.
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lteration in the steroidogenesis pathway and not merely general
ytotoxicity mechanisms.
.  DiscussionThis study evaluated a mechanistic approach to identify repro-
uctive toxicants by examining their effects on steroidogenic gene
xpression and selected steroid output in the H295R cell cul-
ure system. The H295R in vitro cell system is being employed
ig. 5. Prediction of reproductive toxicity does not correlate with general cytotox-
city. Random forest prediction results from the steroidogenesis assay are compared
o a compound concentration causing 50% death in a general cell cytotoxicity assay.-validation. The panels split the compounds in the training set by their true class.
thoughout the world for use in screening enviromental agents for
possible endocrine disruption activity that may  result in develop-
mental and reproductive problems in both humans and wildilfe.
The H295R cell line expresses each of the enzymes in the steroido-
geneic pathway and secretes the hormones of interest at detectable
levels into the culture medium making this an ideal in vitro model
for studying the steroidogenic pathway. The steroidogenic pathway
is made up of multiple enzymes and there are numerous control
points in the production of steroids. The ability to simultaneously
assess the effect of compounds upon multiple steps within the
pathway in vitro and employ a statistic model to correlate these
effects with a toxic/non-toxic in vivo prediction is of great use to
those in the drug development process [35].
We used forskolin and prochloraz, two  compounds well-studied
for their effects on the steroidogenesis pathway, to determine the
effectiveness and robustness of this cell system. Both compounds
were able to differentially induce the transcriptional levels of the
studied enzymes. Forskolin induced a robust increase in proges-
terone and cortisol levels secreted by the H295R cells. Procholaz
induced progesterone, but resulted in dramatic decreases in testos-
terone, DHEA and cortisol. This demonstrated the cell system’s
ability to identify compounds that both increase and decrease
hormone levels. It should be noted that modulators of enzyme
expression are not the same as modulators of enzyme activity. This
assay system does not detect compounds which alter the activity
of an enzyme, except by inferrence from changes in steroid levels
themselves.
Indeed the robust increases in progesterone observed when
treating the H295R cells with prochloraz can not be explained by
the transcriptional changes of the enzymes. CYP17A1, responsible
for its conversion, is increased in expression. However, others have
reported that the hydrolase activity of CYP17A1 is severely inhibited
by similar levels of prochloraz treatment in H295R cells [36]. This
decreased activity is therefore likely the cause for the increases
progesterone levels observed in our system.
We were able to create a model that predicts reproductive tox-
icants with 76% sensitivity and 72% speciﬁcity for an ROC of 0.85
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sing the Random Forest model with all 12 predictors. Using the
aïve Bayes model with the recursive feature elimination includ-
ng only 3 predictors, the ROC drops to only 0.82, yet makes the
ssay easier and more amenable to a highthoughput system by
limating the hormone measurement and limiting the amount of
-PCR required, while matintaining predictive power. Combining
ultiple endpoints from this assay has yielded a model which
redicts better than any one endpoint alone, demonstrating the
ultiparamaeter approach necessary and beneﬁcial. The major-
ty of publications describe the use of screening H295R cells for
ormone measurements only [9,14,37]. Those enlisting these cells
o predict toxic outcomes without incorporating the gene expres-
ion arm are likely missing important information and could likely
eneﬁt from inclusion of a genomics assay.
Finally, we should point out that this assay does not predict only
ompounds with hormonal effects in vivo. Indeed, many of the com-
ounds used here have no evidence of hormonal changes (Table 1).
e  recognize that it’s possible that many of those toxicants with
o detectable hormonal changes may, indeed, produce some sub-
linical alterations in the reproductive hormone economy, changes
hich would not be picked up by the relatively insensitive methods
vailable to investigators (pathology, single-timepoint hormone
easurements, organ weights). In any case, it’s worth noting that
e view this assay as being useful for identifying all reproductive
oxicants, regardless of their degree of hormonal impact. We rec-
gnize the interpretational challenges this poses, but we feel the
ata are compelling.
The  ﬁeld of predictive toxicology has been rapidly develop-
ng. It includes epigenetics, toxicokinetics, genomic biomarkers,
ystems biology, in vitro assays, predictive modeling and computa-
ional science. These techniques are being incorporated more often
n industry as we strive to reduce the costs of drug development
y limiting expensive animal studies to only the most promising
ompounds. This has the added beneﬁt of a reduction in animal
sage. Our goal was to develop and implement an in vitro method to
mploy as early in the drug discovery process as possible to predict
eproductive toxicity. We  characterized the H295R system as an
mpressive model for reproductive toxicity that can be employed to
ank order compounds and to select the safest possible compounds
o be used in animal studies.
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